Iron chelation is an important component of management of transfusion-dependent patients with thalassaemia major. Deferasirox is a relatively new oral iron chelator (US FDA approved in 2005) with the limited experience in children.

**Aims**
To present our experience with deferasirox in patients with thalassaemia major (TM) in the context of: effects on serum ferritin level in chronically transfused patients with thalassaemia major, side effects and patients tolerance to the drug and effects on serum creatinin and liver transaminases.

**Methods**
Four patients with TM with mean age of 3.1 years (range 2.5–3.5) were included in the study. Mean follow up was 37 months (range 29–42). The disease was diagnosed in early childhood (during the first year of life) with the following signs and symptoms: extreme pallor, jaundice, failure to thrive, poor feeding, irritability, decreased activity and hepatosplenomegaly. Regular blood transfusions were applied to treat chronic hemo-lytic anaemia.

**Results**
The mean serum ferritin (SF) at diagnosis was 471.3 ± 284.4 (range 155–706), and at the start of the treatment with deferasirox 6281 ± 9183,9 (range 767–20000). The number of blood transfusions before the treatment was around 28.3 ± 15.5 units (range 17–46), or about 679.3 ± 608.14 (range 220–1369) ml/kg body weight. Deferasirox was given seven days a week at a dose of 20 mg/kg body weight. The primary outcome variable was SF level at the start and at the end of the study. Echocardiography was made in all patients and it was normal. MRI-T2* could not be performed because there was no specific software. The level of SF at the end of the study period was 1312.15 ± 3710. Patients were monitored for hepatic and renal toxicity, visual or auditory changes and development of new symptoms. Adverse events were very mild gastrointestinal symptoms in 1 patient and no adverse events in the remaining 3 patients. Elevation of serum creatinin or hepatic transaminases was not observed in any subject. One patient interrupted the therapy as there was a marked fall in SF < 500 ng/L at the end of the therapy. The treatment was well tolerated; suspension of therapy was not required owing to toxicity.

**Summary/conclusion**
The results suggest that deferasirox is effective in lowering iron burden, it is well tolerated and has a low potential for toxicity. Long term therapy will be needed to assess the benefits on iron balance and organ damage in chronically transfused patients with thalassaemia major.

**PO-0162 CLINICAL PROFILE AND OUTCOME OF CHILDREN WITH ANAPLASTIC LARGE CELL LYMPHOMA**

1. Mathews, 2D Boddu, 3R John, 4N Chadnya, 5M Theres. 1Child Health, Christian Medical College Hospital, Vellore, India; 2Pathology, Christian Medical College Hospital, Vellore, India.

**Background**
Anaplastic large cell lymphoma (ALCL) in children is usually ALK positive and is characterised by advanced disease at presentation with a high incidence of extra nodal involvement. We present the clinical profile, treatment and outcome of a small cohort of children with ALCL treated at our centre between January 2004 and June 2013.

**Results**
19 children, 14 boys and 5 girls, aged 18 months to 14 years, with ALCL. 16/19 had lymphadenopathy and 14/19 had fever. Thirteen had high risk, 5 had standard risk and one had low risk disease. 16/19 ALK positive. 17/19 were treated according to the NHL-BFM 90 protocol. Fourteen completed treatment. Three died during treatment; 2 due to infection and 1 had progressive disease. All 3 had high risk disease and were ALK positive. All the three children with ALK negative disease relapsed; one died on relapse treatment, another was lost to follow up a year after completion of relapse therapy and the third with primary cutaneous disease, is alive and well. Of the 11 ALK positive children who completed treatment, only one relapsed and died. The remaining 10 are alive and well with a mean follow up of 17 months (range 8–93 months).

**Conclusion**
The majority of our patients are ALK positive and have high risk disease at presentation. 55% of children with high risk disease are alive and well after a mean follow up of 17 months. The overall survival was 65% and event free survival 58% at the time of this analysis.

**PO-0163 EFFECT OF NUTRITION WITH FOLLOW-UP FORMULA FROM 6TH MONTH OF AGE ON THE COMPLETE BLOOD COUNT AND IRON LEVELS OF INFANTS (PRELIMINARY TRIAL)**

H Apak, N Ozdemir, G Tuysuz, B Katlibay, E Erginoz, M Kucur. Pediatric Hematology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey

**Background**
We aimed to evaluate the effects of iron overload with deferasirox in patients with thalassaemia major. Deferasirox was given seven days a week at a dose of 20 mg/kg body weight. The primary outcome variable was SF level at the start and at the end of the study. Echocardiography was made in all patients and it was normal. MRI-T2* could not be performed because there was no specific software. The level of SF at the end of the study period was 1312.15 ± 3710. Patients were monitored for hepatic and renal toxicity, visual or auditory changes and development of new symptoms. Adverse events were very mild gastrointestinal symptoms in 1 patient and no adverse events in the remaining 3 patients. Elevation of serum creatinin or hepatic transaminases was not observed in any subject. One patient interrupted the therapy as there was a marked fall in SF < 500 ng/L at the end of the therapy. The treatment was well tolerated; suspension of therapy was not required owing to toxicity.